Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
10.56
-0.17 (-1.58%)
Aug 27, 2026, 4:08 PM HKT

Xuanzhu Biopharmaceutical Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Cash & Equivalents
508.47652.23135.25142.891,125625.5
Short-Term Investments
-0.030.190.07--
Trading Asset Securities
--110.58306.83108.11332.53
Cash & Short-Term Investments
508.47652.27246.02449.81,233958.02
Cash Growth
363.15%165.13%-45.30%-63.53%28.74%680.10%
Accounts Receivable
46.5517.960.42---
Other Receivables
-4.3413.2713.530.920.73
Receivables
46.5522.313.6913.530.955.81
Inventory
86.2886.5257.1962.3250.9430.36
Other Current Assets
69.9471.3252.116.7931.2310.83
Total Current Assets
751.75832.41369542.441,3161,005
Property, Plant & Equipment
107.99115.73172.15197.43153.97127.07
Other Intangible Assets
682.09337.2766.8674.3271.2742.69
Long-Term Deferred Charges
-320.65543.7459.48270.12217.22
Other Long-Term Assets
6.5534.2944.947.3460.1227.46
Total Assets
1,5481,6401,1971,3211,8721,419

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Accounts Payable
138.61113.71102.3269.2117.2517.46
Accrued Expenses
-32.5514.8320.2435.6121.56
Current Portion of Leases
0.220.650.835.15--
Current Income Taxes Payable
-4.531.76-00.03
Current Unearned Revenue
-18.4419.177.25--
Other Current Liabilities
64.7951.9140.3541.27928.18
Total Current Liabilities
203.62221.79179.26143.1361.8667.24
Long-Term Leases
--0.6511.9229.360.04
Long-Term Unearned Revenue
-34.9941.6355.72--
Other Long-Term Liabilities
49.8513.3118.37---
Total Liabilities
253.47270.09239.91210.7691.2267.28

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Common Stock
517.95517.95450.61450.61450.611,413
Additional Paid-In Capital
-2,4821,8901,8902,041664.58
Retained Earnings
--2,326-2,081-1,524-711.3-725.25
Comprehensive Income & Other
776.97696.58696.58293.69-0
Shareholders' Equity
1,2951,370956.711,1101,7811,352
Total Liabilities & Equity
1,5481,6401,1971,3211,8721,419

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2021FY 2020
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Total Debt
0.220.651.4817.0729.360.04
Net Cash (Debt)
508.25651.62244.54432.731,204957.98
Net Cash Growth
367.50%166.47%-43.49%-64.06%25.68%746.80%
Net Cash Per Share
1.031.400.540.963.05-
Filing Date Shares Outstanding
502.27517.95450.61450.61450.61-
Total Common Shares Outstanding
502.27517.95450.61450.61450.61-
Working Capital
548.13610.62189.74399.311,255937.79
Book Value Per Share
2.582.652.122.463.95-
Tangible Book Value
612.821,033889.851,0361,7091,310
Tangible Book Value Per Share
1.221.991.972.303.79-
Buildings
-123.67123.67114.45114.92113.69
Machinery
-127.23126.8126.4785.577.8
Construction In Progress
--1.791.64--
Leasehold Improvements
-3.663.663.66--